文献速递血栓与止血

使用可变风险评估模型或其他策略对外科住院患者进行药物血栓预防的有效性和成本效果决策分析建模

Decision-analysis modeling of effectiveness and cost-effectiveness of pharmacologic thromboprophylaxis for surgical inpatients using variable risk assessment models or other strategies.
PubMed 文献 · J Thromb Haemost · 2023-03-01

该决策分析建模评估成人外科住院患者(排除大型骨科手术、重症监护和孕妇)不同血栓预防策略的成本效果。结果显示对所有合格外科住院患者进行血栓预防在每QALY 20000英镑阈值下有70%概率为最具成本效果策略;基于风险评估模型的预防仅在具有更高敏感性(99.9%)的模型可用时才最具成本效果。作者认为默认推荐药物血栓预防并允许选择退出可能优于复杂的基于风险的选择加入方法。

要点

  • 对所有合格外科住院患者进行血栓预防在每QALY 20000英镑阈值下有70%概率为最具成本效果策略。
  • 基于风险评估模型的预防仅在具有更高敏感性(99.9%)的模型可用时才最具成本效果。
  • 质量调整生命年获益主要来自减少血栓后并发症。

核心结论

  • 对所有合格外科住院患者进行血栓预防似乎是最具成本效果的策略。
  • 默认推荐药物血栓预防并允许选择退出可能优于复杂的基于风险的选择加入方法。

研究设计与样本

  • 决策分析建模,评估成人外科住院患者(排除大型骨科手术、重症监护患者和孕妇)不同血栓预防策略的终生成本和质量调整生命年,模型在英格兰健康和社会照护服务范围内评估。
  • 比较策略包括:无血栓预防、所有患者血栓预防、以及根据风险评估模型(Caprini和Pannucci)给予血栓预防。
  • 假设血栓预防在住院期间给予。

主要发现

  • 对所有外科住院患者进行血栓预防在每QALY 20000英镑阈值下有70%概率为最具成本效果策略。
  • 基于风险评估模型的预防在具有更高敏感性(99.9%)的模型可用于外科住院患者时才最具成本效果。
  • 质量调整生命年获益主要来自减少血栓后并发症。
  • 最优策略对静脉血栓栓塞风险、出血和血栓后综合征风险、预防持续时间及患者年龄等其他因素敏感。

关键数值与推荐

  • 成本效果阈值:每QALY 20000英镑。
  • 对所有外科住院患者进行血栓预防为最具成本效果策略的概率:70%。
  • 基于风险评估模型的预防成为最具成本效果策略所需的模型敏感性:99.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical inpatients are at a risk of venous thromboembolism (VTE), which can be life-threatening or result in chronic complications. Thromboprophylaxis reduces the VTE risk but incurs costs and may increase bleeding risk. Risk assessment models (RAMs) are currently used to target thromboprophylaxis at high-risk patients. OBJECTIVES: To determine the balance of cost, risk, and benefit for different thromboprophylaxis strategies in adult surgical inpatients, excluding patients who underwent major orthopedic surgery or were under critical care and pregnant women. METHODS: Decision analytic modeling was performed to estimate the following outcomes for alternative thromboprophylaxis strategies: thromboprophylaxis usage; VTE incidence and treatment; major bleeding; chronic thromboembolic complications; and overall survival. Strategies compared were as follows: no thromboprophylaxis; thromboprophylaxis for all; and thromboprophylaxis given according to RAMs (Caprini and Pannucci). Thromboprophylaxis is assumed to be given for the duration of hospitalization. The model evaluates lifetime costs and quality-adjusted life-years (QALYs) within England's health and social care services. RESULTS: Thromboprophylaxis for all surgical inpatients had a 70% probability of being the most cost-effective strategy (at a £20 000 per QALY threshold). RAM-based prophylaxis would be the most cost-effective strategy if a RAM with a higher sensitivity (99.9%) were available for surgical inpatients. QALY gains were mainly due to reduced postthrombotic complications. The optimal strategy was sensitive to several other factors such as the risk of VTE, bleeding and postthrombotic syndrome, duration of prophylaxis, and patient age. CONCLUSION: Thromboprophylaxis for all eligible surgical inpatients seemed to be the most cost-effective strategy. Default recommendations for pharmacologic thromboprophylaxis, with the potential to opt-out, may be superior to a complex risk-based opt-in approach.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Davis S, Goodacre S, Horner D, et al. Decision-analysis modeling of effectiveness and cost-effectiveness of pharmacologic thromboprophylaxis for surgical inpatients using variable risk assessment models or other strategies. J Thromb Haemost. 2023. PMID: 36863566. doi:10.1016/j.jtha.2023.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。